Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. - Wikidata - wikimedia - TriplyDB

Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines.

Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines.

http://www.wikidata.org/entity/Q34648125

about

Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?Genetically engineered Newcastle disease virus for malignant melanoma therapy Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses Viral Inhibition of the IFN-Induced JAK/STAT Signalling Pathway: Development of Live Attenuated Vaccines by Mutation of Viral-Encoded IFN-Antagonists Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer Trial Watch:: Oncolytic viruses for cancer therapy Trial Watch-Oncolytic viruses and cancer therapy Generation of mouse small intestinal epithelial cell lines that allow the analysis of specific innate immune functions Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice.Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity.Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses Mitophagy promotes replication of oncolytic Newcastle disease virus by blocking intrinsic apoptosis in lung cancer cells Immunomodulatory effects of Newcastle disease virus AF2240 strain on human peripheral blood mononuclear cells.Safety and clinical usage of newcastle disease virus in cancer therapy Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo.Newcastle Disease Virus V Protein Targets Phosphorylated STAT1 to Block IFN-I Signaling.Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma.Engineered intermonomeric disulfide bonds in the globular domain of Newcastle disease virus hemagglutinin-neuraminidase protein: implications for the mechanism of fusion promotion.Trial watch: Oncolytic viruses for cancer therapy Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model.Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.Engineering oncolytic measles virus to circumvent the intracellular innate immune response.Use of attenuated paramyxoviruses for cancer therapy.Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.Oncolytic viruses & their specific targeting to tumour cells.Evolution of oncolytic viruses: novel strategies for cancer treatment.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Newcastle disease virus interaction in targeted therapy against proliferation and invasion pathways of glioblastoma multiforme.Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.Newcastle Disease Virus Establishes Persistent Infection in Tumor Cells In Vitro: Contribution of the Cleavage Site of Fusion Protein and Second Sialic Acid Binding Site of Hemagglutinin-Neuraminidase.Therapeutic potential of oncolytic Newcastle disease virus: a critical review.Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model.Attenuated measles virus controls pediatric acute B-lineage lymphoblastic leukemia in NOD/SCID mice.

P2860

Q24596171-2B0C1A46-63A2-4539-9050-66DEB858AF0E Q24597831-C5FE5223-F416-4821-83F6-0109D4ABBA06 Q24628144-4306D55B-F841-4568-A330-562E04BC8988 Q24631361-D0F94F97-CA21-4D31-A432-BCDFDC736D7B Q26745547-6071B318-12CF-419A-AAA9-BA37D44D8750 Q26775033-2EE54218-1A95-448B-B0D7-7A743059BBA6 Q26822694-762032FC-CDA7-471C-905C-D508D05D8830 Q27021951-1E80FFCE-82CB-41DE-9C18-007CBD7B7420 Q28072347-594AAAB1-A68E-4737-BB6C-BC15F349B227 Q28535135-CCC69512-EE9B-43B9-A6C1-4CAE206B83F0 Q33523284-63190B5F-4323-4A41-A99D-48E29BA8ACEE Q33931640-E5BE8131-05EF-4009-AEF9-2A71A09588CA Q34028464-EFD272C5-6A88-4C19-918A-6FA81CC49730 Q34110261-9DCD7654-3E18-41B1-B564-950290F7A8B3 Q34227719-487366A9-CCDE-4F14-972A-02220DD93A05 Q34334197-73D8FAAB-A8CF-4E32-8E69-FE0A9471DCF2 Q35498222-5E01DB7F-F4BD-404A-88FE-C3157A990734 Q35699080-ED8574FC-4798-410D-8AD7-5BADB1DA2C6B Q35720107-D835E748-E875-44A1-9DB1-0518F4D20CF9 Q35750051-1F9A8222-AE87-4BB0-A93B-F9D264581AED Q35918371-72A7693F-628E-4BEF-810C-AECDE800BB63 Q36507259-8C9BF328-7B25-4AFC-868E-A624A90AAC52 Q36949597-1955F13A-1D43-42BB-98DE-FD71AD38AAF0 Q37028023-BA9FAD3F-C08F-46B3-80DE-860AB2099932 Q37069810-5D2D8622-BCA8-4387-87EB-B770EC707AB7 Q37133496-B82A0F38-4CC3-4413-A919-3A01A9AB11F9 Q37158473-166AE8E1-22A7-42F3-A61F-992FCFB9FA51 Q37324179-AC967AD7-AF8A-427C-866E-BBB045ABB5D9 Q37810599-49B57FB2-331F-4C52-8A4E-5B5FD75A4DD5 Q37990940-768DEA54-53A8-407F-9F4E-81EF7EDF2FCB Q38061306-9D5C2C6D-2CF9-4CC6-AC27-A62058FB8162 Q38159802-D9941033-7489-4551-87C5-8120AABC38FD Q38223419-248C4141-4AD7-4B0A-BC72-026382BF8705 Q38253056-A2AA539C-B201-46FE-B9C4-72E11F086C24 Q38369289-D41D8E9C-6264-4AF4-86BA-2926383199B7 Q38599166-C8FF54CE-C5B1-4980-8E1E-06E16C833B10 Q38700909-2B83F8A0-4952-4280-AF8A-DD42266F1C6E Q38924554-97AFA346-380E-45B5-8285-DCDC12B4AECF Q38955561-962CA737-D21B-473A-82CC-91AC560D5404 Q39008033-A30D17AD-52B8-4029-A23B-475D07E48FDE

P2860

Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines.

http://www.wikidata.org/entity/Q34648125

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Differentially regulated inter ...... n normal and tumor cell lines.

@ast

Differentially regulated inter ...... n normal and tumor cell lines.

@en

Differentially regulated inter ...... n normal and tumor cell lines.

@nl

type

label

Differentially regulated inter ...... n normal and tumor cell lines.

@ast

Differentially regulated inter ...... n normal and tumor cell lines.

@en

Differentially regulated inter ...... n normal and tumor cell lines.

@nl

prefLabel

Differentially regulated inter ...... n normal and tumor cell lines.

@ast

Differentially regulated inter ...... n normal and tumor cell lines.

@en

Differentially regulated inter ...... n normal and tumor cell lines.

@nl

P1433

Q34648125-1797D894-8C11-4E1E-A4EC-DD98C8B402AD

P1476

Q34648125-B6D91407-2B85-4933-892B-35C33C59C8AA

P2093

Q34648125-0E6C4F0E-0735-459C-9D4C-713BE12072F5

Q34648125-22608662-96B7-4444-A898-69AC1A7DB4E9

Q34648125-75361BB0-83D8-41AD-B380-3FAF7F7A81B8

Q34648125-8EE73C4E-18FB-4771-9481-98679EB20DF7

P2860

Q34648125-02F75EFB-A923-46AD-9ADA-6190C1FCA7FE

Q34648125-0B987035-7EC9-41BD-A664-48B66BEE15FE

Q34648125-139CEADC-CDD1-4FB3-B820-2A2139DED1B3

Q34648125-185EB541-6049-421D-AF1B-FE252E648ABE

Q34648125-18BB92CE-7DCE-439A-8B11-1F8406A86524

Q34648125-28BF0DF8-2F08-4ABD-8266-1C4EC62C1002

Q34648125-38DF2F80-0B04-42CA-B709-1D4FEE366E6E

Q34648125-3A146E04-A06E-46FD-B7CB-1D455270DE6F

Q34648125-3B241A36-3788-4B64-96E7-1C6B2C2A4AC3

Q34648125-4AE4334E-11E1-4390-A8D4-2388C0F53115

P304

Q34648125-C5754647-B1E5-4FD7-BDF3-540E1D2E9763

P31

Q34648125-18405423-210B-43F0-B745-5C947C9470E6

P356

Q34648125-B84CCA39-F439-4688-A953-D11C382ED85B

P407

Q34648125-7D37BE5C-C2C1-49DF-99EE-82FDBF43FDAC

P433

Q34648125-37214515-C9DE-4137-B89E-F9B747158286

P478

Q34648125-3E85E5C8-E1C2-426C-8876-FC570666519A

P577

Q34648125-4263DED8-D2FC-4F79-9C9C-88D299079BE7

P698

Q34648125-C6BA6E25-0E5E-464C-9C20-CDB61FFF7DAD

P932

Q34648125-B090A1D1-6FCE-47E3-817F-2042B412E3AD

P356

P1433

Journal of Virology

P1476

Differentially regulated inter ...... n normal and tumor cell lines.

@en

P2093

Allen Portner

http://www.w3.org/2001/XMLSchema#string

Ruth Ann Scroggs

http://www.w3.org/2001/XMLSchema#string

Sateesh Krishnamurthy

http://www.w3.org/2001/XMLSchema#string

Toru Takimoto

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state

Sequence of the 1918 pandemic influenza virus nonstructural gene (NS) segment and characterization of recombinant viruses bearing the 1918 NS genes

Virus interference. I. The interferon

SOCS proteins: negative regulators of cytokine signaling

Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease

Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway

Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines

Measles virus spread and pathogenesis in genetically modified mice.

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus.

Inhibition of interferon-mediated antiviral responses by influenza A viruses and other negative-strand RNA viruses.

P304

5145-5155

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.02618-05

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

80

http://www.w3.org/2001/XMLSchema#string

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16698995

http://www.w3.org/2001/XMLSchema#string

P932

1472132

http://www.w3.org/2001/XMLSchema#string